Related Experiment Video

Updated: Aug 19, 2026

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Life-saving or life-prolonging? Interpreting trial data and survival curves for patients with congestive heart

C J Malkin1, K S Channer

  • 1Department of Cardiology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK.

European Journal of Heart Failure
|March 15, 2005
PubMed

Insights

Pharmacological therapies for chronic heart failure extend survival, but clinical trials often overlook the total lifetime benefit. This study explores methods to quantify this crucial time benefit in heart failure treatment.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Chronic heart failure (CHF) causes significant global mortality and suffering.
  • Pharmacological therapies like ACE inhibitors and beta-blockers improve outcomes but do not prevent eventual deterioration.
  • Current clinical trials often report risk reduction at fixed time points, not the overall survival benefit.

Purpose of the Study:

  • To discuss the utility of prolongation of life statistics as an outcome measure in heart failure clinical trials.
  • To review methods for calculating the lifetime benefit of pharmacological interventions in CHF.

Main Methods:

  • Review of existing clinical trial data for heart failure.
  • Discussion of statistical techniques for calculating survival prolongation.
  • Analysis of time-to-event data to estimate lifetime benefit.

Main Results:

  • Standard clinical trial endpoints may not fully capture the long-term impact of heart failure therapies.
  • Quantifying the time benefit provides a more comprehensive understanding of treatment efficacy.
  • Simple statistical methods can be applied to major study data to estimate lifetime gains.

Conclusions:

  • Prolongation of life statistics offer a valuable outcome measure for heart failure clinical trials.
  • Accurate calculation of lifetime benefit can better inform treatment decisions and patient expectations.
  • Further emphasis on time-benefit analysis is needed to fully appreciate the impact of CHF therapies.

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...